Exact Mass: 397.2382

Exact Mass Matches: 397.2382

Found 50 metabolites which its exact mass value is equals to given mass value 397.2382, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Tetradeca-9,11-dienedioylcarnitine

3-[(13-carboxytrideca-9,11-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H35NO6 (397.2464)


Tetradeca-9,11-dienedioylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-9,11-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-9,11-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-9,11-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(6E,9E)-Tetradeca-6,9-dienedioylcarnitine

3-[(13-carboxytrideca-6,9-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H35NO6 (397.2464)


(6E,9E)-Tetradeca-6,9-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (6E,9E)-tetradeca-6,9-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6E,9E)-Tetradeca-6,9-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6E,9E)-Tetradeca-6,9-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E,4Z)-Tetradeca-2,4-dienedioylcarnitine

3-[(13-carboxytrideca-2,4-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H35NO6 (397.2464)


(2E,4Z)-Tetradeca-2,4-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (2E,4Z)-tetradeca-2,4-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,4Z)-Tetradeca-2,4-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (2E,4Z)-Tetradeca-2,4-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Tetradecanamidobenzylphosphonic acid

[(4-tetradecanamidophenyl)methyl]phosphonic acid

C21H36NO4P (397.2382)


   

Cyclomarazine A

Cyclomarazine A

C23H31N3O3 (397.2365)


   

(±)14(15)-EET-SI

(±)14(15)-EET-SI

C21H35NO4S (397.2287)


   

Gly Lys Pro Pro

(2S)-1-{[(2S)-1-[(2S)-6-amino-2-(2-aminoacetamido)hexanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

C18H31N5O5 (397.2325)


   

Gly Pro Lys Pro

(2S)-1-[(2S)-6-amino-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}hexanoyl]pyrrolidine-2-carboxylic acid

C18H31N5O5 (397.2325)


   

Gly Pro Pro Lys

(2S)-6-amino-2-{[(2S)-1-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}hexanoic acid

C18H31N5O5 (397.2325)


   

Lys Gly Pro Pro

(2S)-1-{[(2S)-1-{2-[(2S)-2,6-diaminohexanamido]acetyl}pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

C18H31N5O5 (397.2325)


   

Lys Pro Gly Pro

(2S)-1-(2-{[(2S)-1-[(2S)-2,6-diaminohexanoyl]pyrrolidin-2-yl]formamido}acetyl)pyrrolidine-2-carboxylic acid

C18H31N5O5 (397.2325)


   

Lys Pro Pro Gly

2-{[(2S)-1-{[(2S)-1-[(2S)-2,6-diaminohexanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}acetic acid

C18H31N5O5 (397.2325)


   

Pro Gly Lys Pro

(2S)-1-[(2S)-6-amino-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}hexanoyl]pyrrolidine-2-carboxylic acid

C18H31N5O5 (397.2325)


   

Pro Gly Pro Lys

(2S)-6-amino-2-{[(2S)-1-{2-[(2S)-pyrrolidin-2-ylformamido]acetyl}pyrrolidin-2-yl]formamido}hexanoic acid

C18H31N5O5 (397.2325)


   

Pro Lys Gly Pro

(2S)-1-{2-[(2S)-6-amino-2-[(2S)-pyrrolidin-2-ylformamido]hexanamido]acetyl}pyrrolidine-2-carboxylic acid

C18H31N5O5 (397.2325)


   

Pro Lys Pro Gly

2-{[(2S)-1-[(2S)-6-amino-2-[(2S)-pyrrolidin-2-ylformamido]hexanoyl]pyrrolidin-2-yl]formamido}acetic acid

C18H31N5O5 (397.2325)


   

Pro Pro Gly Lys

(2S)-6-amino-2-(2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}acetamido)hexanoic acid

C18H31N5O5 (397.2325)


   

Pro Pro Lys Gly

2-[(2S)-6-amino-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}hexanamido]acetic acid

C18H31N5O5 (397.2325)


   

(±)14(15)-EET-SI

N-(methylsulfonyl)-13-(3-pentyloxiranyl)-5Z,8Z,11Z-tridecatrienamide

C21H35NO4S (397.2287)


   

S32826

P-[[4-[(1-oxotetradecyl)amino]phenyl]methyl]-phosphonic acid

C21H36NO4P (397.2382)


   

3-N-BOC-AMINO-1-[2-AMINO-1-(3-PHENOXY-PHENYL)-ETHYL]-PYRROLIDINE

3-N-BOC-AMINO-1-[2-AMINO-1-(3-PHENOXY-PHENYL)-ETHYL]-PYRROLIDINE

C23H31N3O3 (397.2365)


   

(Methylpyridazine piperidine butyloxyphenyl)ethylacetate

(Methylpyridazine piperidine butyloxyphenyl)ethylacetate

C23H31N3O3 (397.2365)


   

Tetradeca-9,11-dienedioylcarnitine

Tetradeca-9,11-dienedioylcarnitine

C21H35NO6 (397.2464)


   

(6E,9E)-Tetradeca-6,9-dienedioylcarnitine

(6E,9E)-Tetradeca-6,9-dienedioylcarnitine

C21H35NO6 (397.2464)


   

(2E,4Z)-Tetradeca-2,4-dienedioylcarnitine

(2E,4Z)-Tetradeca-2,4-dienedioylcarnitine

C21H35NO6 (397.2464)


   

3-[2-Oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-1,3-diazaspiro[4.6]undecane-2,4-dione

3-[2-Oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-1,3-diazaspiro[4.6]undecane-2,4-dione

C23H31N3O3 (397.2365)


   

N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

C18H31N5O5 (397.2325)


   

N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

C18H31N5O5 (397.2325)


   

N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

C18H31N5O5 (397.2325)


   

N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

C18H31N5O5 (397.2325)


   

(+/-)14(15)-Eet-SI

(+/-)14(15)-Eet-SI

C21H35NO4S (397.2287)


   

N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

C18H31N5O5 (397.2325)


   

N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

C18H31N5O5 (397.2325)


   

N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

C18H31N5O5 (397.2325)


   

N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester

C18H31N5O5 (397.2325)


   

(2S,3S)-1-acetyl-3-[4-(1-cyclopentenyl)phenyl]-2-(hydroxymethyl)-N-propan-2-yl-1,6-diazaspiro[3.3]heptane-6-carboxamide

(2S,3S)-1-acetyl-3-[4-(1-cyclopentenyl)phenyl]-2-(hydroxymethyl)-N-propan-2-yl-1,6-diazaspiro[3.3]heptane-6-carboxamide

C23H31N3O3 (397.2365)


   

(2R,3R)-6-[cyclobutyl(oxo)methyl]-N-cyclopentyl-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptane-1-carboxamide

(2R,3R)-6-[cyclobutyl(oxo)methyl]-N-cyclopentyl-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptane-1-carboxamide

C23H31N3O3 (397.2365)


   

(2R,3R)-1-acetyl-3-[4-(1-cyclopentenyl)phenyl]-2-(hydroxymethyl)-N-propan-2-yl-1,6-diazaspiro[3.3]heptane-6-carboxamide

(2R,3R)-1-acetyl-3-[4-(1-cyclopentenyl)phenyl]-2-(hydroxymethyl)-N-propan-2-yl-1,6-diazaspiro[3.3]heptane-6-carboxamide

C23H31N3O3 (397.2365)


   

1-[(1R)-2-(cyclopropylmethyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-butanone

1-[(1R)-2-(cyclopropylmethyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-butanone

C23H31N3O3 (397.2365)


   

(6R,7R,8S)-N-cyclohexyl-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

(6R,7R,8S)-N-cyclohexyl-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

C23H31N3O3 (397.2365)


   

(6R,7R,8R)-N-cyclohexyl-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

(6R,7R,8R)-N-cyclohexyl-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

C23H31N3O3 (397.2365)


   

(2S,3S)-6-[cyclobutyl(oxo)methyl]-N-cyclopentyl-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptane-1-carboxamide

(2S,3S)-6-[cyclobutyl(oxo)methyl]-N-cyclopentyl-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptane-1-carboxamide

C23H31N3O3 (397.2365)


   

2-[(2-Acetamido-3-hydroxydecoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[(2-Acetamido-3-hydroxydecoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium

C17H38N2O6P+ (397.2467)


   

2-[[2-(Butanoylamino)-3-hydroxyoctoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-(Butanoylamino)-3-hydroxyoctoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C17H38N2O6P+ (397.2467)


   

2-[Hydroxy-[3-hydroxy-2-(propanoylamino)nonoxy]phosphoryl]oxyethyl-trimethylazanium

2-[Hydroxy-[3-hydroxy-2-(propanoylamino)nonoxy]phosphoryl]oxyethyl-trimethylazanium

C17H38N2O6P+ (397.2467)


   

4-Tetradecanamidobenzylphosphonic acid

4-Tetradecanamidobenzylphosphonic acid

C21H36NO4P (397.2382)


   
   
   

ST 19:0;O4;Gly

ST 19:0;O4;Gly

C21H35NO6 (397.2464)


   

(3s,6s)-5-hydroxy-6-[(2r)-3-hydroxy-2-methylpropyl]-1-methyl-3-{[1-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-3,6-dihydropyrazin-2-one

(3s,6s)-5-hydroxy-6-[(2r)-3-hydroxy-2-methylpropyl]-1-methyl-3-{[1-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-3,6-dihydropyrazin-2-one

C23H31N3O3 (397.2365)